NTRB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	8 747.00
Średni wolumen	46 685.00
Kapitalizacja rynkowa	27.34M
EPS	$0 ( 2024-04-24 )
Następna data zysków	( $0 ) 2024-06-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.21
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-09	Goodman Gerald	Buy	20 000	Stock Option
2022-08-16	Goodman Gerald	Buy	23 333	Stock Option
2022-01-21	Goodman Gerald	Buy	11 167	Stock Option
2021-10-22	Goodman Gerald	Buy	87 500	CS Purchase Warrant
2023-10-27	Goodman Gerald	Buy	49 500	Stock Option

INSIDER POWER
90.09
Last 21 transactions
Buy: 293 666 \| Sell: 1 500 500

Nutriband Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nutriband Inc. Finanse

Annual	2023
Przychody:	$2.09M
Zysk brutto:	$818 893 (39.27 %)
EPS:	$-0.690

FY	2023
Przychody:	$2.09M
Zysk brutto:	$818 893 (39.27 %)
EPS:	$-0.690

FY	2022
Przychody:	$2.08M
Zysk brutto:	$750 409 (36.08 %)
EPS:	$-0.570

FY	2022
Przychody:	$1.42M
Zysk brutto:	$504 310 (35.46 %)
EPS:	$-1.060

Financial Reports:

No articles found.

Nutriband Inc.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.